Acasti Pharma Announces Full Exercise of Over-Allotment Option
May 14, 2018 13:23 ET
|
Acasti Pharma Inc.
NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE U.S. LAVAL, Quebec, May 14, 2018 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (NASDAQ:ACST) (TSXV:ACST) (the “Company” or...
Acasti Pharma Announces Closing of $10 Million Underwritten Offering
May 09, 2018 12:42 ET
|
Acasti Pharma Inc.
NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE U.S. LAVAL, Quebec, May 09, 2018 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (NASDAQ:ACST) (TSXV:ACST) (the “Company” or...
Acasti Pharma Prices $10 Million Underwritten Offering
April 24, 2018 12:17 ET
|
Acasti Pharma Inc.
NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE U.S. LAVAL, Quebec, April 24, 2018 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (NASDAQ:ACST) (TSXV:ACST) (the “Company” or...
Acasti Pharma Announces Overnight Marketed Public Unit Offering
April 23, 2018 16:11 ET
|
Acasti Pharma Inc.
NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE U.S. Laval, QUEBEC, April 23, 2018 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (NASDAQ:ACST) (TSXV:ACST) (the “Company” or...
Acasti Announces Third Quarter Results
January 12, 2016 17:07 ET
|
Acasti Pharma Inc.
Important progress made with FDA on CaPre® development pathwayAmended IND application to commence bioavailability bridging study submittedEntered into licensing agreement with Neptune to market...
Acasti & Neptune Enter Into Transactional Arrangement & Sign Operational Agreements
January 07, 2016 19:11 ET
|
Acasti Pharma Inc.
Supports Neptune in financing transaction by granting limited recourse pledge in the amount of $2.0M CDNEntered into positive operational arrangements with Neptune, including a licensing...
Acasti Provides Update on CaPre® Development Pathway
December 16, 2015 07:50 ET
|
Acasti Pharma Inc.
Encouraging response from FDA on CaPre® clinical developmentSeeking formal approval to commence bioavailability bridging study LAVAL, Quebec, Dec. 16, 2015 (GLOBE NEWSWIRE) -- Acasti Pharma Inc....
Acasti Granted Composition & Use Patent in Japan, Taiwan and Mexico
December 01, 2015 07:30 ET
|
Acasti Pharma Inc.
LAVAL, Québec, Dec. 1, 2015 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. ("Acasti" or the "Corporation") (NASDAQ:ACST) (TSX-V:APO), an emerging biopharmaceutical company focused on the research,...
Acasti Announces Second Quarter Results
October 14, 2015 17:10 ET
|
Acasti Pharma Inc.
Important progress made in FDA discussions on development pathway for CaPre®
Reverse Stock Split effective October 15, 2015
LAVAL, Quebec, Oct. 14, 2015 (GLOBE NEWSWIRE) -- Acasti...
Acasti Announces 1-for-10 Reverse Stock Split
September 29, 2015 07:00 ET
|
Acasti Pharma Inc.
LAVAL, Quebec, Sept. 29, 2015 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. ("Acasti" or the "Corporation") (NASDAQ:ACST) (TSX-V:APO), an emerging biopharmaceutical company focused on the research,...